Lineage Cell Therapeutics (LCTX) Operating Margin Growth (5y) (2015 - 2026)

Lineage Cell Therapeutics (LCTX) Operating Margin Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Lineage Cell Therapeutics 251.15 Mn 188.44 Mn 1.73 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 136,290.00
Dec 31, 2025 155,781.00
Sep 30, 2025 107,491.00
Jun 30, 2025 94,318.00
Mar 31, 2025 101,399.00
Dec 31, 2024 37,557.00
Sep 30, 2024 138,375.00
Jun 30, 2024 97,240.00
Mar 31, 2024 91,382.00
Dec 31, 2023 102,868.00
Sep 30, 2023 51,656.00
Jun 30, 2023 20,323.00
Mar 31, 2023 146,014.00
Dec 31, 2022 66,527.00
Sep 30, 2022 40,633.00
Jun 30, 2022 218,467.00
Mar 31, 2022 325,985.00
Dec 31, 2021 96,374.00
Sep 30, 2021 36,163.00
Jun 30, 2021 -15,284.00